Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Account Payables: 2010-2025

Historic Change in Account Payables for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $55000.0.

  • OptimizeRx's Change in Account Payables rose 12444.44% to $55000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 326000.0%. This contributed to the annual value of -$72000.0 for FY2024, which is 9454.55% up from last year.
  • As of Q3 2025, OptimizeRx's Change in Account Payables stood at $55000.0, which was up 12444.44% from -$1.4 million recorded in Q2 2025.
  • Over the past 5 years, OptimizeRx's Change in Account Payables peaked at $1.3 million during Q2 2024, and registered a low of -$1.4 million during Q2 2025.
  • Its 5-year average for Change in Account Payables is -$30487.9, with a median of -$118971.0 in 2021.
  • In the last 5 years, OptimizeRx's Change in Account Payables skyrocketed by 107464.22% in 2022 and then plummeted by 419346.93% in 2023.
  • Over the past 5 years, OptimizeRx's Change in Account Payables (Quarter) stood at -$164837.0 in 2021, then soared by 433.27% to $549354.0 in 2022, then tumbled by 183.92% to -$461000.0 in 2023, then fell by 29.93% to -$599000.0 in 2024, then soared by 109.18% to $55000.0 in 2025.
  • Its last three reported values are $55000.0 in Q3 2025, -$1.4 million for Q2 2025, and $1.2 million during Q1 2025.